Consistent with the in vitro data, administration of CD155 CAR-T cells resulted in significantly reduced tumor burden and extended survival in mice bearing A549 (Figure 5, F–H) and Capan-1 (Figure 5, I–K) tumors, compared with those treated with mock T cells. This evidence concerns the gene PVR and neoplasm.